Alnylam Pharmaceuticals | ALNY - Gross Profit On Sales

Stock Price
322.38
Daily Change
-4.87 -1.49%
Monthly
0%
Yearly
42.47%
Q2 Forecast
309.25

Alnylam Pharmaceuticals reported $829.31M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Incyte USD 1.39B 118.68M Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
Moderna USD 226M 583M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Novartis USD 10.82B 694M Sep/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Sanofi EUR 8.45B 3.02B Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Takeda JPY 790.55B 262.97B Dec/2025
Tectonic Therapeutic USD 0 0 Mar/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025
Xencor USD 21M 22.61M Sep/2025